Corcept Therapeutics Inc (CORT)
54.79
-1.66
(-2.94%)
USD |
NASDAQ |
Nov 14, 16:00
54.44
-0.35
(-0.64%)
After-Hours: 20:00
Corcept Therapeutics Net Income (TTM): 141.82M for Sept. 30, 2024
Net Income (TTM) Chart
Historical Net Income (TTM) Data
| Date | Value |
|---|---|
| September 30, 2024 | 141.82M |
| June 30, 2024 | 125.98M |
| March 31, 2024 | 118.02M |
| December 31, 2023 | 106.14M |
| September 30, 2023 | 91.39M |
| June 30, 2023 | 94.62M |
| March 31, 2023 | 94.50M |
| December 31, 2022 | 101.42M |
| September 30, 2022 | 116.87M |
| June 30, 2022 | 112.73M |
| March 31, 2022 | 111.84M |
| December 31, 2021 | 112.51M |
| September 30, 2021 | 106.45M |
| June 30, 2021 | 97.61M |
| March 31, 2021 | 99.41M |
| December 31, 2020 | 106.01M |
| September 30, 2020 | 109.40M |
| June 30, 2020 | 114.11M |
| March 31, 2020 | 105.97M |
| December 31, 2019 | 94.18M |
| September 30, 2019 | 86.81M |
| June 30, 2019 | 78.22M |
| March 31, 2019 | 76.22M |
| December 31, 2018 | 75.41M |
| September 30, 2018 | 151.73M |
| Date | Value |
|---|---|
| June 30, 2018 | 147.74M |
| March 31, 2018 | 142.19M |
| December 31, 2017 | 129.12M |
| September 30, 2017 | 35.39M |
| June 30, 2017 | 24.22M |
| March 31, 2017 | 12.55M |
| December 31, 2016 | 8.14M |
| September 30, 2016 | 4.502M |
| June 30, 2016 | 1.316M |
| March 31, 2016 | -1.597M |
| December 31, 2015 | -6.408M |
| September 30, 2015 | -11.26M |
| June 30, 2015 | -16.67M |
| March 31, 2015 | -22.28M |
| December 31, 2014 | -31.38M |
| September 30, 2014 | -38.61M |
| June 30, 2014 | -43.51M |
| March 31, 2014 | -47.86M |
| December 31, 2013 | -46.01M |
| September 30, 2013 | -46.01M |
| June 30, 2013 | -43.40M |
| March 31, 2013 | -39.10M |
| December 31, 2012 | -38.05M |
| September 30, 2012 | -36.86M |
| June 30, 2012 | -35.00M |
Net Income Definition
Net Income is the total amount of profit earned by a company. This metric boils down to the overall profit that is left from the revenue that a company receives after taking out various operational line items like cost of goods sold, income tax expense, SG&A expense, etc. Eventually, all companies would want to have a consistent positive and growing net income, so that this can be used for various purposes like reinvesting into the company, paying off debt, and potentially paying out dividends to shareholders.
Net Income (TTM) Range, Past 5 Years
91.39M
Minimum
Sep 2023
141.82M
Maximum
Sep 2024
108.05M
Average
106.30M
Median
Net Income (TTM) Benchmarks
| Catalyst Pharmaceuticals Inc | 142.80M |
| ADMA Biologics Inc | 68.13M |
| Akebia Therapeutics Inc | -45.99M |
| Bioventus Inc | -39.48M |
| Alnylam Pharmaceuticals Inc | -332.26M |